Adaptimmune Strengthens Board with Appointment of Barbara

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Adaptimmune Strengthens Board with Appointment of Barbara Duncan

PHILADELPHIA and OXFORD, United Kingdom, May 24, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP ) (“Adaptimmune” or the “Company”), a leader in T-cell therapy to treat cancer, today announced the appointment of Barbara Duncan to its Board of Directors as an independent Non-Executive Director effective from June 23, 2016. Ms. Duncan will also serve as a member of the Audit Committee.

“We are delighted that Barbara Duncan has agreed to join our Board of Directors,” commented Dr. Jonathan Knowles, Adaptimmune’s Chairman. “Her substantial financial and accounting expertise, combined with extensive experience in the life sciences sector, will augment well the skills and experience of our other Board members.”

“I am very pleased to join Adaptimmune at this exciting time in the Company’s development,” said Ms. Duncan. “I look forward to working with the team to support advancement of Adaptimmune’s clinical programs and help to progress the next growth stage of operations in the United Kingdom and USA.”

Barbara Duncan has over 15 years of experience in the life sciences industry. She has served as Chief Financial Officer and Treasurer at Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT ) since May 2009. Ms. Duncan currently serves as a director for public company, Medgenics, Inc. (NYSE: MDGN ) and for privately held Edgemont Pharmaceuticals, LLC. She previously served as Chief Financial Officer and then Chief Executive Officer at DOV Pharmaceuticals, Inc. from 2001 to 2009. Before that, she served as Vice President of Corporate Finance - Global Healthcare at Lehman Brothers Inc. and as Director of Corporate Finance at SBC Warburg Dillon Read Inc. Ms. Duncan holds a Master of Business Administration from the Wharton School of the University of Pennsylvania and a Bachelor of Business Administration from Louisiana State University.

About Adaptimmune Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its SPEAR™ (Specific Peptide Enhanced Affinity Receptor) T-cell platform. Established in 2008, the company aims to utilize the body’s own machinery - the T-cell - to target and destroy cancer cells by using engineered, increased affinity TCRs as a means of strengthening natural patient T-cell responses. Adaptimmune’s lead program is a SPEAR T-cell therapy targeting the NY-ESO cancer antigen. Its NY-ESO SPEAR T-cell therapy has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types, including synovial sarcoma and multiple myeloma. Adaptimmune has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO TCR program. In addition, Adaptimmune has a number of proprietary programs. The company has identified over 30 intracellular target peptides preferentially expressed in cancer cells and is currently progressing 12 through unpartnered research programs. Adaptimmune has over 200 employees and is located in Oxfordshire, U.K. and Philadelphia, USA. For more information: http://www.adaptimmune.com

Forward-Looking Statements This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 12, 2016, and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.

Adaptimmune Contacts Will Roberts Vice President, Investor Relations T:  (215) 825-9306  E: will.roberts@adaptimmune.com Margaret Henry Head of PR T: +44 (0)1235 430036 Mobile: +44 (0)7710 304249 E: margaret.henry@adaptimmune.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Copper Peptides Shine in New Renue Blue Cream

Updated Category News Views 171

Renue By Science's Ambitious Skincare Launch Alright, we've got a big player stepping up in the realm of skincare with a new face cream packed tightly with science-backed goodies. Renue By Science is revamping their game by anchoring their new Renue Blue Face Cream around the star of the moment: copper tripeptide-1, also known as GHK-Cu. This is more than a beauty gloss...

Continue Reading
Elah Holdings' Q3 2026 Report Sparks Investor Interest

Updated Category News Views 79

Elah Holdings Drops Their Q3 2026 Numbers Eat your heart out, folks—Elah Holdings has just dropped their third quarter report for 2026, and it caught some eyes. This ain't your run-of-the-mill, brush-right-past-it release. They're out there, waving their flag high in the competitive marketplace, trying to tell us they mean business. If you missed the announcement, they...

Continue Reading
Cracking Life Insurance Needs: John Dorsa's Insights

Updated Category News Views 137

Life Insurance: A Necessary Puzzle Life’s uncertainties have a way of putting a wrench in our plans, and nothing screams uncertainty like figuring out life insurance. But fret not! HelloNation’s got insights on this financial maze, and they’ve roped in insurance pro John Dorsa from Ridgeland to help out. Calculating Coverage Needs Forget the one-size-fits-all...

Continue Reading
Choate's Expands to New Mid-South Markets

Updated Category News Views 171

Family Traditions Drive Choate's Growth Back in the day, you might've thought the family-run businesses were a dying breed, right? Not in the case of Choate's Air Conditioning, Heating, Plumbing & Electrical. These folks aren't just holding the fort; they're storming new territories across the Mid-South like they've got something to prove—or maybe just something to...

Continue Reading
Texxon Faces Revenue Slide Amid Strategic Shifts

Updated Category News Views 155

Texxon's Strategic Transitions and Financial Headaches Texxon Holding Limited (NASDAQ:NPT) just laid their cards on the table, unveiling a mixed bag in their fiscal year 2026 results. As the world's chemical and plastics scene faces winds of change, Texxon buckled down and tried to steer the ship clear from the rocks. It's a balancing act juggling market headwinds, a new...

Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron

Updated Category News Views 359

A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...

Continue Reading
AI Alliance Rethinks Health Plan Engagement

Updated Category News Views 139

Building Bridges in Healthcare Ever seen healthcare stuck in its own muck with disconnected gears attempting to move the same machine? Well, that's precisely the mountain healthplans.ai and URAWARRIOR aim to climb down from. Founders Rachel Spilo and Dr. Bershan Shaw are gearing up to shake hands in their no-nonsense, real-world vow to sync member engagement with the...

Continue Reading
The Melt Grabs Top Spot in Burger Ratings War

Updated Category News Views 122

Burger Battle: The Melt Claims Victory When you're in the cutthroat world of fast-casual dining, grabbing the top spot on any list is no small potatoes. The Melt did just that, snatching the title of America’s Highest-Rated Burger Spot. Based on an in-depth analysis of Google and Yelp reviews, folks have spoken, loud and clear, over the past two years. It's a world...

Continue Reading
Philadelphia Firm Targets 100 Toys for Children This Holiday

Updated Category News Views 0

A hundred unopened toys can look modest on paper, yet that is exactly why this Philadelphia effort lands differently than the usual chest-thumping corporate charity chatter. van der Veen, Hartshorn & Levin has set a clear holiday target: collect 100 new, unwrapped toys for children in the Philadelphia area through the U.S. Marine Corps Reserve Toys for Tots program. No...

Continue Reading
LifeVac's 7,000 Reported Saves Deserve Careful Context

Updated Category News Views 0

Veggie straws are supposed to be harmless until they are not. LifeVac says a 19-month-old girl in South Dakota became unable to breathe on November 14 after eating the snack, with a sticky piece creating a complete airway obstruction. Her father retrieved the family's LifeVac, used the pediatric mask while she was on her back, and the company says one application...

Continue Reading

Top 5 Most Recently Viewed Articles

Epson Robots Unveils Cutting-Edge Automation Tech at Expo

Updated Category News Views 360

Innovative Automation Solutions by Epson Robots Epson Robots is set to showcase its latest high-performance automation solutions at an upcoming major tradeshow. The focus will be on the exciting advancements in the SCARA and 6-Axis robots, which are recognized globally for their efficiency and precision in various industries. Exciting New Product Launches At the event,...

Continue Reading
Rexel Reports Fourth Quarter Growth Amid Market Challenges

Updated Category News Views 313

Rexel's Financial Performance Overview Rexel has released its fourth quarter (Q4) and full year (FY) financial results, showcasing strong performance amid challenging market conditions. The company's FY 2024 sales reached €19,285.1 million, reflecting a modest year-on-year increase of 0.7% on a reported basis. This growth narrative underscores Rexel's effective...

Continue Reading
Monster Beverage Sees Gains in 2025 First Quarter Results

Updated Category News Views 313

Monster Beverage's Impressive First Quarter Growth 2025 First Quarter Highlights The financial landscape for Monster Beverage Corporation (NASDAQ: MNST) revealed compelling growth in the first quarter of 2025. Gross profit as a percentage of net sales improved significantly, reaching 56.5 percent. The company reported an operating income increase of 5.1 percent, totaling...

Continue Reading
Transforming Metastatic HR+/HER2- Breast Cancer Care Innovations

Updated Category News Views 215

Transforming Treatment Strategies for Metastatic HR+/HER2- Breast Cancer In recent years, the landscape of metastatic HR+/HER2- breast cancer treatment has evolved dramatically. With innovative therapies coming to the forefront, patients now have access to a wider range of treatment options that aim to improve survival rates and quality of life. The rise of targeted...

Continue Reading
Oil Price Surge Driven by Manufacturing Growth in China

Updated Category News Views 193

Understanding the Recent Trends in Oil Prices Oil prices experienced an uptick recently, driven by promising signs from China's manufacturing sector. Reports reveal that China's factory activity demonstrated growth in December, marking it as a significant development in the global oil landscape. However, despite this positive news, oil prices are on a trajectory to finish...

Continue Reading